Antiandrogen Therapy

Phase 3Small molecule

Antiandrogen Therapy is one of 137 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

136

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Prostate CarcinomaRecruiting

Metastatic Prostate CancerActive, not recruiting

Prostate CancerActive, not recruiting

Biochemically Recurrent Prostate CarcinomaRecruiting

Prostate AdenocarcinomaPhase 3

Active, not recruiting

Prostate CarcinomaPhase 2

Recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Biochemically Recurrent Prostate CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Antiandrogen Therapy

UUniversity of Washington

Phase 3

11 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Metastatic Prostate Cancer

NCT03456843

Q4 2027

Phase 2Active, not recruiting

Prostate Cancer

NCT03541850

Q1 2028

Phase 2Recruiting

Prostate Cancer

NCT06244004

Q2 2028

Phase 2Recruiting

Prostate Cancer

NCT07202247

Phase 2Recruiting

Prostate Carcinoma

NCT04947254

Clinical

Trials by Indication[1]

Prostate Cancer11 trials

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT02472275·8 enrolled

Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

Unknown status·PPeter MacCallum Cancer Centre, Australia·Phase 3·NCT00110162·2,000 enrolled

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01409200·73 enrolled

Show 8 more trials

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Recruiting·NNorthwestern University·Phase 2·NCT06244004·125 enrolled

Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases

Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 3·NCT00685646·227 enrolled

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Terminated·TThomas Jefferson University·Phase 2·NCT05676463·6 enrolled

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT03541850·92 enrolled

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Recruiting·—·Phase 2·NCT07202247·60 enrolled

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

Terminated·UUniversity of Utah·Phase 2·NCT03827473·1 enrolled

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Terminated·UUniversity of Washington·Phase 2·NCT03649841·10 enrolled

Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

Unknown status·CCancer Research UK·N/A·NCT00967954·120 enrolled

Metastatic Prostate Cancer4 trials

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

Completed·UUniversity of Washington··NCT00392938·11 enrolled

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Active, not recruiting·YYale University·Phase 2·NCT03456843·190 enrolled

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

Completed·UUNICANCER·Phase 3·NCT00104715·385 enrolled

Show 1 more trial

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Active, not recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT04267887·7 enrolled

High Risk1 trial

Post-operative or Early Salvage XRT and ADT for High Risk PCa

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00949962·87 enrolled

Biochemically Recurrent Prostate Carcinoma1 trial

Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical Prostatectomy

Recruiting·MMayo Clinic·Phase 3·NCT06205316·118 enrolled

Prostate Carcinoma1 trial

Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04947254·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Antiandrogen Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiandrogen Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiandrogen Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Washington

Antiandrogen Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Prostate Cancer11 trials

Metastatic Prostate Cancer4 trials

High Risk1 trial

Biochemically Recurrent Prostate Carcinoma1 trial

Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News